Cafepharma Today

June 24 2019 - Better than Ambien? Minerva soars on insomnia med trial update
Minerva soars on insomnia med trial update
Bristol-Myers selling off blockbuster Otezla
Two $86M IPOs
Opdivo fails matchup with Nexavar aimed at shaking up HCC liver disease market
*please scroll down for all the latest news*
*scroll through previous pages at the bottom to get older news*

Want to stay updated on CP happenings? New features, new boards, CP wire articles, and more? Click here to subscribe

Today's most popular searches:

Current News

submit a press release

Click here to stay updated on CP happenings
FDA Action Alert: Regeneron, Sanofi, Celgene
BioSpace
Monday, June 24, 2019 - 7:27pm
tags:
FDA, drug approvals, Acer Therapeutics, Edsivo, Regeneron, Sanofi, Dupixent, Celgene, Revlimid, Alexion, Soliris, Dova Pharmaceuticals, Doptelet, Nabriva Therapeutics, Contepo, Retrophin, Thiola
J&J depression drug Spravato gets half-hearted backing from VA doctors despite Trump's zeal
Fierce Pharma
Monday, June 24, 2019 - 7:21pm
tags:
JNJ, Spravato, Veteran's Affairs, Donald Trump, depression
Conatus Pharma to explore options as liver disease drug fails trial
Yahoo/Reuters
Monday, June 24, 2019 - 7:20pm
tags:
Conatus Pharmaceuticals, clinical trials, NASH, emricasan, Novartis
FDA Updates List of Off-Patent, Off-Exclusivity Drugs Without Generic Competition
RAPS.org
Monday, June 24, 2019 - 7:15pm
tags:
FDA, generics, competition
Drugmakers Call for Changes to FDA Bioavailability Guidance
RAPS.org
Monday, June 24, 2019 - 7:14pm
tags:
FDA, bioavailability
GSK wins speedy FDA Zejula review in ovarian cancer niche
Fierce Pharma
Monday, June 24, 2019 - 7:13pm
tags:
GSK, FDA, Zejula, ovarian cancer, late-stage ovarian cancer, Tesaro
Better than Ambien? Minerva soars on PhIIb update on seltorexant for insomnia
Endpoints
Monday, June 24, 2019 - 11:33am
tags:
Minerva, insomnia, clinical trials, seltorexant
Bristol-Myers star Opdivo fails survival test in a matchup with Nexavar aimed at shaking up the big HCC market
Endpoints
Monday, June 24, 2019 - 11:25am
tags:
Bristol-Myers Squibb, Opdivo, Bayer, Nexavar, liver cancer, clinical trials
In surprise switch, Bristol-Myers is selling off blockbuster Otezla, promising to complete Celgene acquisition — just later
Endpoints
Monday, June 24, 2019 - 11:23am
tags:
Bristol-Myers Squibb, Opdivo, Otezla, M&A, FTC, Celgene
Why are elite athletes different than the rest of us? Take a look at their microbes
Stat
Monday, June 24, 2019 - 11:18am
tags:
microbiome, athletes
Evotec forms Oxford initiative to spawn AI-enabled startups
Fierce Biotech
Monday, June 24, 2019 - 11:16am
tags:
Evotec, Sensyne Health, artificial intelligence, start-ups
In $86M IPO pitch, Mirum spells out plans to turn Shire discards into orphan liver drug successes
Endpoints
Monday, June 24, 2019 - 11:14am
tags:
Mirum, IPOs, Shire, liver disease
AbbVie gets a green light to resume recruiting patients for one myeloma study — but Venclexta remains under a cloud
Endpoints
Monday, June 24, 2019 - 10:54am
tags:
AbbVie, Venclexta, Multiple Myeloma, FDA, clinical trials
Microbiome Report for Week Ending 6/22/19
CP Wire
Monday, June 24, 2019 - 10:51am
tags:
microbiome, Axial Biotherapeutics, EnteroBiotix, Seres Therapeutics, Synlogic, Ginkgo Bioworks
These 3 Biotech Stocks Skyrocketed Last Week
Motley Fool
Monday, June 24, 2019 - 9:42am
tags:
Array Biopharma, Pfizer, M&A, G1 Therapeutics, trilaciclib, Cel-Sci
Bayer begins phase 3 trial testing aflibercept in infant blindness
Pharmaforum
Monday, June 24, 2019 - 9:39am
tags:
Bayer, clinical trials, infant blindness, Aflibercept, retinopathy of prematurity
UPDATED: FDA spurns hay fever drug from India's Glenmark
Endpoints
Monday, June 24, 2019 - 9:38am
tags:
FDA, Glenmark, India, Ryaltris
Why This New FDA-approved Drug Vyleesi Is Not 'Female Viagra'
Forbes
Monday, June 24, 2019 - 9:36am
tags:
Vyleesi, female sexual dysfunction, HSDD, Amag Pharmaceuticals
Genetic Disease Focused Fulcrum Therapeutics Files for $86 Million IPO
CP Wire
Monday, June 24, 2019 - 9:32am
tags:
Fulcrum Therapeutics, IPOs, FSHD, sickle cell disease, beta thalassemia
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
Yahoo/Benzinga
Sunday, June 23, 2019 - 2:04pm
tags:
Merck, Keytruda, Melinta Therapeutics, Amag Pharmaceuticals, Palatin, Acer Therapeutics, Sanofi, Regeneron, Alexion, Pfizer, Roche, Navidea Biopharmaceuticals, Ascendis Pharma, Scholar Rock, Adaptive Biotechnologies, BridgeBio, IPOs, G Medical Innovations, Karuna, Morphic Therapeutics

Pages

Latest CP Wire Articles

Microbiome Report for Week Ending 6/22/19
Genetic Disease Focused Fulcrum Therapeutics Files for $86 Million IPO
Polaris Partners Files for New $400 Million Fund
Karuna Therapeutics Raises Its IPO Estimate to $85 Million
Change Healthcare Updates Filing for $1.2 Billion IPO and Equity Offering
Microbiome-Focused Seres Therapeutics Inc. Announces Proposed Common Stock Offering
Money Continues to Pour Into Life Science Funds – Bain Capital Raises $900 Million
Ramaswamy's Dermavant Updates $124 Million IPO Filing
Personalis Updates $122 Million IPO Filing
Third Rock Ventures Launches $770 Million Biotech Fund

Latest Pharmagather Articles

CBI’s 5th Annual 340B Manufacturer Summit
Drug Channels
On a Double Mission: Chris Round, Merck KGaA, Darmstadt, Germany
pharmexec top feature
An Idiotic Exhibit
In the Pipeline
The Most Synthetically Complex Drug Candidate Ever
In the Pipeline
New 340B Health Reports Confirms the Program’s Size—But Double-Dips on Hospitals’ Community Benefit Obligations
Drug Channels
Unto the Fourth Generation – in Nematodes
In the Pipeline
Patents and Prophecy
In the Pipeline
Clinical Evidence Key to Commercializing Life Science Products
pharmexec marketing
Meet the Top Ten Drugs of 2024 (Maybe)
Drug Channels
Pharma Jobs from Indeed


Pharma and Device News from NASDAQ

Medovex’s Transition to H-CYTE Underscores Biotechnology Focus
Monday, June 24, 2019 - 8:00am
Axsome Therapeutics Initiates GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder
Monday, June 24, 2019 - 7:00am
FDA Grants Face-to-Face Meeting to Discuss CytoDyn’s 510(k) Application for ProstaGene™ Prognostic Test
Monday, June 24, 2019 - 6:00am
Savaria Declares Its Monthly Dividend
Friday, June 21, 2019 - 8:00am
Geron Appoints Vice President, Human Resources
Thursday, June 20, 2019 - 4:27pm
Phase Genomics Accelerates Microbiome Discovery and Antibiotic Resistance tracking with New ProxiMeta™ 8-Pack Including Bundled Analysis
Thursday, June 20, 2019 - 9:05am
BeyondSpring Set to Join FTSE Russell 3000® Index
Thursday, June 20, 2019 - 8:00am
Arbutus receives regulatory clearance to initiate Phase 1a/1b Clinical Trial of AB-729
Thursday, June 20, 2019 - 7:30am
CytoDyn Submits 510(k) Pre-Submission Application to U.S. FDA for ProstaGene™ Prognostic Test
Wednesday, June 19, 2019 - 9:02am
Incysus Therapeutics Announces Publication of U.S. Patent for Drug Resistant Immunotherapy (DRI) Technology
Wednesday, June 19, 2019 - 8:00am

Breaking Healthcare News - powered by Seeking Alpha

Applied Therapeutics net loss widens in Q1
Friday, June 21, 2019 - 9:38am
Labcorp gains a sell-side bull
Friday, June 21, 2019 - 9:12am
Immutep nabs new patent in Australian
Friday, June 21, 2019 - 8:51am
Updated Epizyme data from tazemetostat Phase 2 trial 'positive'
Friday, June 21, 2019 - 8:41am
Canopy Growth down 6% premarket on fiscal Q4 results
Friday, June 21, 2019 - 8:30am
Ocular +7.8% as DEXTENZA gains an indication
Friday, June 21, 2019 - 8:29am
Ocular Therapeutix +10% after FDA approves sNDA application
Friday, June 21, 2019 - 8:25am
Drug companies file suit to block disclosure of drug prices in TV ads
Friday, June 14, 2019 - 6:16pm
Marker Therapeutics -3.5% after $200M mixed shelf
Friday, June 14, 2019 - 5:32pm
AstraZeneca to invest $630M in South Korean health industry - Bloomberg
Friday, June 14, 2019 - 5:16pm

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.